Objective:

To evaluate the efficacy and safety of Erxiekang Emplastra as adjunctive therapy for acute gastroenteritis (AGE) in children aged 1 to 14 years.

Approach:

Key Findings:

• Exposed group had significantly shorter diarrhea duration (3.83 vs. 4.92 days, p < 0.01).
• Exposed group had lower 3-day MVS (2.90 vs. 4.51, p < 0.01).
• Adjunctive Erxiekang Emplastra was independently associated with reduced diarrhea duration (β = –0.38, p < 0.01) and lower 3-day MVS (β = –0.44, p < 0.01).
• Only 1.44% of patients developed mild transient local reactions, with no severe adverse events reported.

Interpretation:

Remove this section.

Limitations:

• Single-center study may limit generalizability.
• Retrospective design may introduce bias.

Conclusion:

Rephrase to align with the source's wording without adding implications.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.